Campus Virchow-Klinikum, Medizinische Klinik M S Hämatologie und Onkologie Augustenburger Platz 1, 13353 Berlin, Germany.
Expert Rev Anticancer Ther. 2010 Apr;10(4):485-91. doi: 10.1586/era.10.27.
Pancreatic adenocarcinoma is one of the most aggressive tumors, with a high potential for early dissemination and a relatively poor sensitivity to radiation therapy and cytotoxic agents. Complete resection of the tumor is currently the only curative option but only 10-15% of patients present with localized, potentially resectable disease at the time of diagnosis. Median overall survival for all resected patients (R0 and R1) averages between 11 and 23 months, 5-year overall survival ranges from 10 to 25% (R0) and 0 to 5% (R1), leading to a case-fatality index of 95%. Despite the latest trend toward adjuvant chemotherapy with gemcitabine due to the results from the Charité Onkologie-001 trial, there is no broad consensus regarding the adjuvant regimen that should be applied. Early data from the European Study Group for Pancreatic Cancer-3(v2) trial revealed no difference in terms of overall survival between 5-fluorouracil/folinic acid and gemcitabine after resection of pancreatic cancer.
胰腺腺癌是最具侵袭性的肿瘤之一，具有早期扩散的高潜力，对放射治疗和细胞毒性药物的敏感性相对较差。肿瘤的完全切除是目前唯一的治愈方法，但只有 10-15%的患者在诊断时出现局部、潜在可切除的疾病。所有接受手术切除的患者（R0 和 R1）的中位总生存期平均为 11 至 23 个月，5 年总生存率为 10 至 25%（R0）和 0 至 5%（R1），导致病死率指数为 95%。尽管由于 Charité Onkologie-001 试验的结果，最近出现了使用吉西他滨进行辅助化疗的趋势，但对于应应用的辅助方案仍没有广泛共识。来自欧洲胰腺癌研究组-3(v2)试验的早期数据显示，在胰腺腺癌切除术后，5-氟尿嘧啶/亚叶酸和吉西他滨在总生存期方面没有差异。
